Heritage Wealth Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$38.6K Hold
1,050
﹤0.01% 361
2025
Q4
$53.4K Hold
1,050
﹤0.01% 316
2025
Q3
$58.3K Hold
1,050
﹤0.01% 291
2025
Q2
$72.5K Hold
1,050
﹤0.01% 270
2025
Q1
$72.9K Sell
1,050
-800
-43% -$66.1K ﹤0.01% 271
2024
Q4
$159K Hold
1,850
0.01% 223
2024
Q3
$220K Hold
1,850
0.01% 203
2024
Q2
$264K Hold
1,850
0.01% 179
2024
Q1
$238K Hold
1,850
0.01% 198
2023
Q4
$191K Hold
1,850
0.01% 218
2023
Q3
$168K Hold
1,850
0.01% 212
2023
Q2
$150K Hold
1,850
0.01% 227
2023
Q1
$147K Hold
1,850
0.01% 229
2022
Q4
$125K Hold
1,850
0.01% 246
2022
Q3
$92.2K Hold
1,850
0.01% 257
2022
Q2
$103K Buy
+1,850
New +$103K 0.01% 255
2020
Q1
Sell
-178
Closed -$5.15K 542
2019
Q4
$5.15K Buy
+178
New +$4.93K ﹤0.01% 442
2019
Q3
Sell
-640
Closed -$16.3K 459
2019
Q2
$16.3K Hold
640
﹤0.01% 356
2019
Q1
$16.7K Hold
640
﹤0.01% 322
2018
Q4
$14K Hold
640
﹤0.01% 286
2018
Q3
$15K Buy
+640
New +$15.6K ﹤0.01% 282

Other funds holding NVO

Heritage Wealth Advisors's NVO Position: Q1 2026 in Review

Heritage Wealth Advisors held its Novo Nordisk (NVO) position steady in Q1 2026 at 1,050 shares worth $38.6K. The position accounts for ﹤0.01% of the portfolio, ranked #361.

Heritage Wealth Advisors first reported a position in NVO in Q3 2018 and has held it in 21 quarters since. The position peaked at $264K in Q2 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Heritage Wealth Advisors held 1,050 shares of Novo Nordisk worth $38.6K as of Q1 2026.
  • Heritage Wealth Advisors left its Novo Nordisk share count unchanged in Q1 2026.
  • Novo Nordisk made up ﹤0.01% of Heritage Wealth Advisors's portfolio in Q1 2026, its #361 holding.
  • Heritage Wealth Advisors first reported a position in Novo Nordisk in Q3 2018 and has held it in 21 quarters since.
  • Heritage Wealth Advisors's Novo Nordisk position peaked at $264K in Q2 2024.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Heritage Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.